Search

Your search keyword '"Zinzani, Pier L."' showing total 46 results
Start Over Author "Zinzani, Pier L."
46 results on '"Zinzani, Pier L."'

1. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

Author

Locke, Frederick L., Filosto, Simone, Chou, Justin, Vardhanabhuti, Saran, Perbost, Regis, Dreger, Peter, Hill, Brian T., Lee, Catherine, Zinzani, Pier L., Kröger, Nicolaus, López-Guillermo, Armando, Greinix, Hildegard, Zhang, Wangshu, Tiwari, Gayatri, Budka, Justin, Marincola, Francesco M., To, Christina, Mattie, Mike, Schupp, Marco, Cheng, Paul, Bot, Adrian, Shen, Rhine, Bedognetti, Davide, Miao, Harry, and Galon, Jérôme

Published
2024
Full Text
View/download PDF

2. Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

Author

Chaganti, Sridhar, Barlev, Arie, Caillard, Sophie, Choquet, Sylvain, Cwynarski, Kate, Friedetzky, Anke, González-Barca, Eva, Sadetsky, Natalia, Schneeberger, Stefan, Thirumalai, Dhanalakshmi, Zinzani, Pier L., and Trappe, Ralf U.

Published
2023
Full Text
View/download PDF

3. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Author

Zelenetz, Andrew D., Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., Jiménez, Javier L., Bishton, Mark, Dholaria, Bhagirathbhai, Mengarelli, Andrea, Phillips, Tycel J., Sungala, Nagendraprasad, Musuraca, Gerardo, Sheehy, Oonagh, Van Den Neste, Eric, Odera, Mitsuhiko, Miao, Lu, Gold, Daniel P., Ghalie, Richard G., and Zinzani, Pier L.

Published
2024
Full Text
View/download PDF

4. Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France

Author

Peyronel, Francesco, primary, Haroche, Julien, additional, Campochiaro, Corrado, additional, Pegoraro, Francesco, additional, Amoura, Zahir, additional, Tomelleri, Alessandro, additional, Mazzariol, Martina, additional, Papo, Matthias, additional, Cavalli, Giulio, additional, Benigno, Giuseppe D., additional, Fenaroli, Paride, additional, Grigoratos, Chrysanthos, additional, Mengoli, Maria C., additional, Bonometti, Arturo, additional, Berti, Emilio, additional, Savino, Gustavo, additional, Cives, Mauro, additional, Neri, Iria, additional, Pacinella, Gaetano, additional, Tuttolomondo, Antonino, additional, Marano, Massimo, additional, Muratore, Francesco, additional, Manfredi, Andreina, additional, Broccoli, Alessandro, additional, Zinzani, Pier L., additional, Didona, Biagio, additional, Massaccesi, Chiara, additional, Buono, Andrea, additional, Ammirati, Enrico, additional, Di Lernia, Vito, additional, Dagna, Lorenzo, additional, Vaglio, Augusto, additional, and Cohen-Aubart, Fleur, additional

Published
2023
Full Text
View/download PDF

6. Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.

Author

Kuipers, Maria T., Spanjaart, Anne M., Bonifazi, Francesca, diBlasi, Roberta, Zinzani, Pier L., Thieblemont, Catherine, Baudet, Mathilde, Biemond, Bart J., Kok, Wouter E. M., and Kersten, Marie J.

Subjects
CARDIAC patients, ARRHYTHMIA, T cells, CD19 antigen, LYMPHOMAS, DIFFUSE large B-cell lymphomas, CARDIAC magnetic resonance imaging
Abstract

This document discusses the feasibility of using CD19 CAR T-cell therapy in patients with cardiac lymphoma. The article highlights that cardiac non-Hodgkin lymphoma is not well-represented in medical literature, and the exact incidence is unknown. The authors present three cases of patients with cardiac lymphoma who received CAR T-cell therapy. The first two patients had successful outcomes with no significant cardiac events, while the third patient experienced severe cardiotoxicity after CAR T infusion. The authors suggest that a multidisciplinary approach and preventive measures for severe cytokine release syndrome are important in optimizing the safety and efficacy of CAR T-cell therapy in patients with cardiac lymphoma. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Author

Mato, Anthony R., primary, Woyach, Jennifer A., additional, Brown, Jennifer R., additional, Ghia, Paolo, additional, Patel, Krish, additional, Eyre, Toby A., additional, Munir, Talha, additional, Lech-Maranda, Ewa, additional, Lamanna, Nicole, additional, Tam, Constantine S., additional, Shah, Nirav N., additional, Coombs, Catherine C., additional, Ujjani, Chaitra S., additional, Fakhri, Bita, additional, Cheah, Chan Y., additional, Patel, Manish R., additional, Alencar, Alvaro J., additional, Cohen, Jonathon B., additional, Gerson, James N., additional, Flinn, Ian W., additional, Ma, Shuo, additional, Jagadeesh, Deepa, additional, Rhodes, Joanna M., additional, Hernandez-Ilizaliturri, Francisco, additional, Zinzani, Pier L., additional, Seymour, John F., additional, Balbas, Minna, additional, Nair, Binoj, additional, Abada, Paolo, additional, Wang, Chunxiao, additional, Ruppert, Amy S., additional, Wang, Denise, additional, Tsai, Donald E., additional, Wierda, William G., additional, and Jurczak, Wojciech, additional

Published
2023
Full Text
View/download PDF

8. Genomic profiling for clinical decision making in lymphoid neoplasms

Author

de Leval, Laurence, primary, Alizadeh, Ash A., additional, Bergsagel, P. Leif, additional, Campo, Elias, additional, Davies, Andrew, additional, Dogan, Ahmet, additional, Fitzgibbon, Jude, additional, Horwitz, Steven M., additional, Melnick, Ari M., additional, Morice, William G., additional, Morin, Ryan D., additional, Nadel, Bertrand, additional, Pileri, Stefano A., additional, Rosenquist, Richard, additional, Rossi, Davide, additional, Salaverria, Itziar, additional, Steidl, Christian, additional, Treon, Steven P., additional, Zelenetz, Andrew D., additional, Advani, Ranjana H., additional, Allen, Carl E., additional, Ansell, Stephen M., additional, Chan, Wing C., additional, Cook, James R., additional, Cook, Lucy B., additional, d’Amore, Francesco, additional, Dirnhofer, Stefan, additional, Dreyling, Martin, additional, Dunleavy, Kieron, additional, Feldman, Andrew L., additional, Fend, Falko, additional, Gaulard, Philippe, additional, Ghia, Paolo, additional, Gribben, John G., additional, Hermine, Olivier, additional, Hodson, Daniel J., additional, Hsi, Eric D., additional, Inghirami, Giorgio, additional, Jaffe, Elaine S., additional, Karube, Kennosuke, additional, Kataoka, Keisuke, additional, Klapper, Wolfram, additional, Kim, Won Seog, additional, King, Rebecca L., additional, Ko, Young H., additional, LaCasce, Ann S., additional, Lenz, Georg, additional, Martin-Subero, José I., additional, Piris, Miguel A., additional, Pittaluga, Stefania, additional, Pasqualucci, Laura, additional, Quintanilla-Martinez, Leticia, additional, Rodig, Scott J., additional, Rosenwald, Andreas, additional, Salles, Gilles A., additional, San-Miguel, Jesus, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Semenzato, Gianpietro, additional, Staudt, Louis M., additional, Swerdlow, Steven H., additional, Tam, Constantine S., additional, Trotman, Judith, additional, Vose, Julie M., additional, Weigert, Oliver, additional, Wilson, Wyndham H., additional, Winter, Jane N., additional, Wu, Catherine J., additional, Zinzani, Pier L., additional, Zucca, Emanuele, additional, Bagg, Adam, additional, and Scott, David W., additional

Published
2022
Full Text
View/download PDF

9. Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Author

Bishton, Mark J., primary, Salles, Gilles, additional, Golfier, Camille, additional, Knauf, Wolfgang, additional, Bocchia, Monica, additional, Turner, Deborah, additional, Slama, Borhane, additional, Harchowal, Jatinder, additional, Marshall, Scott, additional, Bosi, Alberto, additional, Lleonart, Juan José Bargay, additional, Welslau, Manfred, additional, Kim, SooKyoung, additional, Lee, Young N., additional, Zinzani, Pier L., additional, and Laribi, Kamel, additional

Published
2022
Full Text
View/download PDF

10. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Author

Alderuccio, Juan P., primary, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Lunning, Matthew A., additional, Hess, Brian T., additional, Zinzani, Pier L., additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Hamadani, Mehdi, additional, Kahl, Brad S., additional, Ungar, David, additional, Kilavuz, Turk, additional, Yu, Eric, additional, Qin, Yajuan, additional, and Caimi, Paolo F., additional

Published
2022
Full Text
View/download PDF

11. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinʼs Lymphoma

Author

Connors, Joseph M., Jurczak, Wojciech, Straus, David J., Ansell, Stephen M., Kim, Won S., Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L., Cunningham, David, Rosta, Andras, Josephson, Neil C., Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A., Huebner, Dirk, and Radford, John

Published
2018
Full Text
View/download PDF

12. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Author

Wang, Michael L., primary, Jurczak, Wojciech, additional, Jerkeman, Mats, additional, Trotman, Judith, additional, Zinzani, Pier L., additional, Belada, David, additional, Boccomini, Carola, additional, Flinn, Ian W., additional, Giri, Pratyush, additional, Goy, Andre, additional, Hamlin, Paul A., additional, Hermine, Olivier, additional, Hernández-Rivas, José-Ángel, additional, Hong, Xiaonan, additional, Kim, Seok Jin, additional, Lewis, David, additional, Mishima, Yuko, additional, Özcan, Muhit, additional, Perini, Guilherme F., additional, Pocock, Christopher, additional, Song, Yuqin, additional, Spurgeon, Stephen E., additional, Storring, John M., additional, Walewski, Jan, additional, Zhu, Jun, additional, Qin, Rui, additional, Henninger, Todd, additional, Deshpande, Sanjay, additional, Howes, Angela, additional, Le Gouill, Steven, additional, and Dreyling, Martin, additional

Published
2022
Full Text
View/download PDF

13. Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.

Author

Chaganti, Sridhar, Barlev, Arie, Caillard, Sophie, Choquet, Sylvain, Cwynarski, Kate, Friedetzky, Anke, González-Barca, Eva, Sadetsky, Natalia, Schneeberger, Stefan, Thirumalai, Dhanalakshmi, Zinzani, Pier L., and Trappe, Ralf U.

Abstract

Introduction: Following hematopoietic stem cell transplantation or solid organ transplantation, patients are at risk of developing Epstein–Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), which is an ultra-rare and potentially lethal hematologic malignancy. Common treatments for EBV+ PTLD include rituximab alone or combined with chemotherapy. Given specific considerations for this population, including severity of the underlying condition requiring transplant, the rigors of the transplant procedure, as well as risks to the transplanted organ, there is a group of patients with EBV+ PTLD for whom chemotherapy may be inappropriate; however, there is limited information characterizing these patients. This study aimed to reach expert consensus on the key characteristics of patients for whom chemotherapy may be inappropriate in a real-world setting. Methods: A two-round modified Delphi study was conducted to reach consensus among clinicians with expertise treating EBV+ PTLD. Articles identified in a targeted literature review guided the development of round 1 and 2 topics and related statements. The consensus threshold for round 1 statements was 75.0%. If consensus was achieved in round 1, the statement was not discussed further in round 2. The consensus thresholds for round 2 were moderate (62.5–75.0%), strong (87.5%), or complete (100.0%). Results: The panel was composed of a total of eight clinicians (seven hematologists/hemato-oncologists) from six European countries. The panel generated a final list of 43 consensus recommendations on the following topics: terminology used to describe patients for whom chemotherapy may be inappropriate; demographic characteristics; organ transplant characteristics; comorbidities that preclude the use of chemotherapy; EBV+ PTLD characteristics; and factors related to treatment-related mortality and morbidity. Conclusions: This modified Delphi panel successfully achieved consensus on key topics and statements that characterized patients with EBV+ PTLD for whom chemotherapy may be inappropriate. These recommendations will inform clinicians and aid in the treatment of EBV+ PTLD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Author

Tiacci, Enrico, Park, Jae H., De Carolis, Luca, Chung, Stephen S., Broccoli, Alessandro, Scott, Sasinya, Zaja, Francesco, Devlin, Sean, Pulsoni, Alessandro, Chung, Young R., Cimminiello, Michele, Kim, Eunhee, Rossi, Davide, Stone, Richard M., Motta, Giovanna, Saven, Alan, Varettoni, Marzia, Altman, Jessica K., Anastasia, Antonella, Grever, Michael R., Ambrosetti, Achille, Rai, Kanti R., Fraticelli, Vincenzo, Lacouture, Mario E., Carella, Angelo M., Levine, Ross L., Leoni, Pietro, Rambaldi, Alessandro, Falzetti, Franca, Ascani, Stefano, Capponi, Monia, Martelli, Maria P., Park, Christopher Y., Pileri, Stefano A., Rosen, Neal, Foà, Robin, Berger, Michael F., Zinzani, Pier L., Abdel-Wahab, Omar, Falini, Brunangelo, and Tallman, Martin S.

Published
2015
Full Text
View/download PDF

17. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

Author

Tiacci, Enrico, primary, De Carolis, Luca, additional, Simonetti, Edoardo, additional, Capponi, Monia, additional, Ambrosetti, Achille, additional, Lucia, Eugenio, additional, Antolino, Agostino, additional, Pulsoni, Alessandro, additional, Ferrari, Samantha, additional, Zinzani, Pier L., additional, Ascani, Stefano, additional, Perriello, Vincenzo M., additional, Rigacci, Luigi, additional, Gaidano, Gianluca, additional, Della Seta, Roberta, additional, Frattarelli, Natalia, additional, Falcucci, Paolo, additional, Foà, Robin, additional, Visani, Giuseppe, additional, Zaja, Francesco, additional, and Falini, Brunangelo, additional

Published
2021
Full Text
View/download PDF

19. Fludarabine Plus Cyclophosphamide and Rituximab in Waldenstrom Macroglobulinemia: An Effective but Myelosuppressive Regimen to be Offered to Patients With Advanced Disease

Author

Tedeschi, Alessandra, Benevolo, Giulia, Varettoni, Marzia, Battista, Marta L., Zinzani, Pier L., Visco, Carlo, Meneghini, Vittorio, Pioltelli, Pietro, Sacchi, Stefano, Ricci, Francesca, Nichelatti, Michele, Zaja, Francesco, Lazzarino, Mario, Vitolo, Umbero, and Morra, Enrica

Published
2012
Full Text
View/download PDF

22. 90 Y‐ibritumomab tiuxetan in patients with extra‐nodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) — The Zeno Study

Author

Lolli, Ginevra, primary, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Marangon, Miriam, additional, Pellegrini, Cinzia, additional, Morigi, Alice, additional, Casadei, Beatrice, additional, Nanni, Laura, additional, Stefoni, Vittorio, additional, Carella, Matteo, additional, Cavo, Michele, additional, and Zinzani, Pier L., additional

Published
2020
Full Text
View/download PDF

24. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma

Author

Gobbi, Paolo G., Broglia, Chiara, Di Giulio, Giuseppe, Mantelli, Monica, Anselmo, Paola, Merli, Francesco, Zinzani, Pier L., Rossi, Gabriele, Callea, Vincenzo, Iannitto, Emilio, Paulli, Marco, Garioni, Lorena, and Ascari, Edoardo

Subjects
Tumor staging -- Research, Hodgkin's disease -- Prognosis, Hodgkin's disease -- Drug therapy, Health
Published
2004

25. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

Author

Connors, Joseph M, Jurczak, Wojciech, Straus, David J, Ansell, Stephen M, Kim, Won S, Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L, Cunningham, David, Rosta, Andras, Josephson, Neil C, Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A, Huebner, Dirk, Radford, John, Luminari, Stefano, DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., and Radford, J.

Subjects
Male, Oncology, medicine.medical_treatment, chemistry.chemical_compound, Immunologic Factor, 0302 clinical medicine, Brentuximab vedotin, anti-CD30, Brentuximab vedotin, Aged, 80 and over, Medicine (all), Orvostudományok, General Medicine, Middle Aged, Hodgkin Disease, Vinblastine, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, Female, Human, medicine.drug, Adult, medicine.medical_specialty, Neutropenia, Adolescent, Klinikai orvostudományok, Bleomycin, Disease-Free Survival, Article, Follow-Up Studie, Young Adult, 03 medical and health sciences, Internal medicine, medicine, anti-CD30, Survival rate, Aged, Neoplasm Staging, Chemotherapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hodgkin's lymphoma, medicine.disease, Immunoconjugate, chemistry, ABVD, Doxorubicin, business, 030215 immunology
Abstract

none 29 si This article was published on December 10, 2017. All ECHELON-1 investigators are listed in the Supplementary Appendix, available at NEJM.org Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. Results At a median follow-up of 24.9 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P=0.03). There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 0.72 [95% CI, 0.44 to 1.17]; P=0.19). All secondary efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 patients who received primary prophylaxis with granulocyte colony-stimulating factor than among those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who had peripheral neuropathy had resolution or improvement at the last follow-up visit. Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were associated with pulmonary-related toxicity. Conclusions A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at 2 years. (Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.gov number, NCT01712490 ; EudraCT number, 2011-005450-60 .). mixed Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group

Published
2018

27. 90Y‐ibritumomab tiuxetan in patients with extra‐nodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) — The Zeno Study.

Author

Lolli, Ginevra, Argnani, Lisa, Broccoli, Alessandro, Marangon, Miriam, Pellegrini, Cinzia, Morigi, Alice, Casadei, Beatrice, Nanni, Laura, Stefoni, Vittorio, Carella, Matteo, Cavo, Michele, and Zinzani, Pier L.

Subjects
MUCOSA-associated lymphoid tissue lymphoma, GRANULOCYTE-colony stimulating factor
Abstract

90Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study Keywords: 90Y-ibritumomab tiuxetan; extra-nodal marginal zone B-cell lymphoma; MALT lymphoma; relapsed; treatment-naïve EN 90Y-ibritumomab tiuxetan extra-nodal marginal zone B-cell lymphoma MALT lymphoma relapsed treatment-naïve e6 e9 4 03/31/20 20200401 NES 200401 Marginal zone lymphomas (MZL) represent about 17% of all non-Hodgkin lymphomas (NHL) (Zinzani & Broccoli, [8]) and are composed of three different entities: splenic MZL, nodal MZL and marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In conclusion, YIT represents a highly effective and tolerable treatment option for MALT lymphoma, in a setting where currently there are no standard treatments and the therapy options are limited, especially in R/R patients. [Extracted from the article]

Published
2020
Full Text
View/download PDF

29. Radioimmunotherapy for Follicular Lymphoma Achieves Long Term Lymphoma Control in First Line and at Relapse: 8 Year Follow Up Data of 281 Patients from the International RIT-Registry

Author

hohloch, karin, primary, Windemuth-Kiesselbach, Christiane, additional, Kolz, Julia, additional, Zinzani, Pier L., additional, Caccione, Roberto, additional, Jurczak, Woijciech, additional, Bischof-Delalaoye, Angelika, additional, Truemper, Lorenz, additional, and Scholz, Christian W., additional

Published
2018
Full Text
View/download PDF

30. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

Author

Ceriani, Luca, primary, Martelli, Maurizio, additional, Conconi, Annarita, additional, Zinzani, Pier L., additional, Ferreri, Andrés J. M., additional, Botto, Barbara, additional, Stelitano, Caterina, additional, Gotti, Manuel, additional, Cabras, Maria G., additional, Rigacci, Luigi, additional, Giovanella, Luca, additional, Zucca, Emanuele, additional, and Johnson, Peter W. M., additional

Published
2017
Full Text
View/download PDF

31. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Author

Awan, Farrukh T, Hillmen, Peter, Hellmann, Andrzej, Robak, Tadeusz, Hughes, Steven G., Trone, Denise, Shannon, Megan, Flinn, Ian W., Byrd, John C., Riveros, Dardo, Pavlovsky, Santiago, Iastrebner, Claudio M., Carney, Dennis A., Deveridge, Sandra, Durrant, Simon, Hahn, Uwe H., Hertzberg, Mark, Leahy, Michael F., David, Ma, Marlton, Paula, Mulligan, Stephen, Opat, Stephen S., Tiley, Campbell, Wickham, Nicholas W., Cannell, Paul, Gatalano, John, Catalano, John, Cull, Gavin, Luen B., To, Hopfinger, Georg, Jager, Ulrich, Linkesch, Werner, Petzer, Andreas, Schwarzmeier, Josef, Steurer, Michael, Greil, Richard, Bememan, Zwi, Bosly, Andre, Bron, Dominique, Janssens, Ann, Offner, Fritz, Van Den Neste, Eric W., Ka Lung, Wu, Van Hoof, Achiel, Maiolino, Angelo, Pinczowski, Helio, Zanichelli, Maria A., Pereira, Juliana, Larratt, Loree, Spaner, David, Howson Jan, Kang, Chen, Christine I., Cantin, Guy, Fernandez, Louis A., Fraser, Graeme, Mayer, Jiri, Trneny, Marek, Jebavy, Ladislav, Bordessoule, Dominique, Lamy, Thierry, Milpied, Noel, Truchan Graczyk, Malgorzata, Eghbali, Houchingue, Karsenti, Jean Michel, Celigny, Philippe Solal, Mans, Le, Cazin, Bruno, Gyan, Emmanuel, Lepretre, Stephane, Bergmann, Lothar, Tsionos, Konstantinos, Lokeshwar, Nilesh M., Agarwal, Mohan B., Ross, Cecil R., Deshmukh, Chetan D., Narayanan, Geetha, Raina, Vinod, Bondarde, Shailesh A., Shah, Bhavin A., Bairey, Osnat, Tikva, Petach, Shvidel, Lev, Ambrosetti, Achille, Rossi, Policlinico G. B., Angelucci, Emanuele, Carella, Angelo M., Massaia, Massimo, Zinzani, Pier L., Caligaris Cappio, Federico, Foa, Roberto, Gaidano, Gianluca, della Caritá, A. O. Maggiore, Leone, Giuseppe, Santoro, Armando, Griskevicius, Laimonas, Jurgutis, Romualdas, Baker, Bartrum W., Hawkins, Timothy, Corbett, Gillian M., Ganly, Peter, D'Souza, Alvyn B., Deptala, Andrzej, Holowiecki, Jerzy, Kloczko, Janusz, Skotnicki, Aleksander, Zdziarska, Barbara, Kyrcz Krzemien, Slawomira, Dmoszynska, Anna, Moreira, Anna, Pereira, Ana P., Colita, Andrei, Moicean, Andreea D., Vasilica, Mariana, Danaila, Catalin, Gheorghita, Emanuil, Pavlov, Vyacheslav V., Rossiev, Viktor A., Konstantinova, Tatiana, Samoilova, Olga S., Novgorod, Nizhniy, Shelekhova, Tatyana, Zaritsky, Andrey Y., Abdulkadyrov, Kudrat M., Zyuzgin, Ilya S., Pristupa, Alexander S., Loscertales, Javier, Vidal, Joan Besalduch, de Mallorca, Palma, Gonzalez, Marcos, Ortuno, Francisco, Giraldo, Pilar, Nathwani, Amit, Agrawal, Samir G., Rule, Simon, Dearden, Claire E., Bloor, Adrian J., Haynes, Andrew, Singer, Charles, Boclek, Robert G., Bosserman, Linda D., Chan, David, Davidson, Sheldon J., Dichmann, Robert A., Farber, Charles, Hart, Lowell, Hermann, Robert, Eddie, Hu, Janakiraman, Nalini, Jonas, William, Liem, Kiem D., Mcintyre, Rosemary E., O'Brien, Susan, Patel, Giribala, Rado, Thomas, Schilder, Russell, Smith, Scott E., Stock, Wendy, Turturro, Francesco, Venugopal, Parameswaran, Anderson, Thomas C., Berry, William, Boyd, Thomas E., Byrd, John, Cooper, Maureen, Flinn, Ian, Gersh, Robert, Gordon, David, Guzley, Gregory J., Wilks, Sharon T., Klein, Andreas, Krauss, John C., Lister, John, Mandell, Lance, Molina, Arthur, Cooper, Barry, Pendergrass, Kelly B., Reeder, Craig, Savin, Michael A., Spitzer, Gary, Tuscano, Joseph M., Vandeventer, Hendrik, Eradat, Herbert A., Masood, Aisha, Mena, Raul, F. T. Awan, P. Hillmen, A. Hellmann, T. Robak, S. G. Hughe, D. Trone, M. Shannon, I. W. Flinn, J. C. Byrd, L. U. C., and Riveros D, Iastrebner CM, Carney DA, Deveridge S, Durrant S, Hahn UH, Hertzberg M, Leahy MF, Ma D, Marlton P, Mulligan S, Opat SS, Tiley C, Wickham NW, Cannell P, Gatalano J, Cull G, B To L, Catalano J, Wickham NW, Hopfinger G, Jager U, Linkesch W, Petzer A, Schwarzmeier J, Steurer M, Greil R, Bememan Z, Bosly A, Bron D, Janssens A, Offner F, Van Den Neste EW, Wu KL, Van Hoof A, Maiolino A, Pinczowski H, Zanichelli MA, Pereira J, Larratt L, Spaner D, Howson-Jan K, Chen CI, Fernandez LA, Fraser G, Mayer J, Trneny M, Jebavy L, Bordessoule D, Lamy T, Milpied N, Eghbali H, Karsenti JM, Celigny PS, Cazin B, Gyan E, Lepretre S, Bergmann L, Tsionos K, Lokeshwar NM, Agarwal MB, Ross CR, Deshmukh CD, Narayanan G, Raina V, Bondarde SA, Shah BA, Bairey O, Ben-Yehuda D, Shvidel L, Ambrosetti A, Angelucci E, Carella AM, Massaia M, Zinzani PL, Caligaris-Cappio F, Foa R, Gaidano G, Leone G, Santoro A, Griskevicius L, Jurgutis R, Baker BW, Hawkins T, Corbett GM, Ganly P, D'Souza AB, Deptala A, Hellmann A, Holowiecki J, Kloczko J, Skotnicki A, Zdziarska B, Robak T, Dmoszynska A, Moreira I, Pereira AP, Colita A, Moicean AD, Gheorghita E, Vasilica M, Pavlov VV, Rossiev VA, Konstantinova T, Samoilova OS, Novgorod N, Shelekhova T, Zaritsky AY, Abdulkadyrov KM, Zyuzgin IS, Pristupa AS, Loscertales J, Casado LF, Gonzalez M, Ortuno F, Giraldo P, Servet M, Nathwani A, Howson-Jan K, Agrawal SG, Hillmen P, Rule S, Dearden CE, Bloor AJ, Haynes A, Singer C, Boclek RG, Bosserman LD, Chan D, Davidson SJ, Dichmann RA, Farber C, Guzley GJ, Hermann R, Hu E, Janakiraman N, Jonas W, Liem KD, Mcintyre RE, O'Brien S, Patel G, Rado T, Schilder R, Smith SE, Stock W, Turturro F, Venugopal P, Berry W, Boyd TE, Byrd J, Cooper M, Flinn I, Gersh R, Gordon D, Wilks ST, Klein A, Krauss JC, Lister J, Mandell L, Molina A, Pendergrass KB, Reeder C, Savin MA, Spitzer G, Tuscano JM, van Deventer H, Eradat HA, Cooper B, Masood A, Mena R.

Subjects
Oncology, Male, Chronic lymphocytic leukaemia, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Pharmacology, Antibodies, Monoclonal, Murine-Derived, Recurrence, hemic and lymphatic diseases, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, drug therapy, Male, Middle Aged, Recurrence, Vidarabine, Chronic, Aged, 80 and over, Leukemia, Medicine (all), Antibodies, Monoclonal, Hematology, Middle Aged, Adult, Aged, Aged, Lymphocytic, Fludarabine, Tolerability, Small lymphocytic lymphoma, administration /&/ dosage/adverse effects, Female, Humans, Leukemia, Rituximab, Female, Vidarabine, medicine.drug, Adult, Murine-Derived, medicine.medical_specialty, Cyclophosphamide, chemical and pharmacologic phenomena, CD23, Lumiliximab, Aged, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, chronic lymphocytic leukaemia, lumiliximab, small lymphocytic lymphoma, Internal medicine, administration /&/ dosage/adverse effects/analogs /&/ derivatives, 80 and over, Antibodie, Adverse effect, Lymphocytic leukaemia, business.industry, administration /&/ dosage/adverse effects, Antibodie, B-Cell, administration /&/ dosage/adverse effects, Cyclophosphamide, Interim analysis, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocol, business
Abstract

Item does not contain fulltext Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) versus FCR alone in subjects with relapsed CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre study of lumiliximab in combination with FCR versus FCR alone in patients with relapsed CLL. Six hundred and twenty-seven patients were randomized to either arm. Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete response rate 16% vs. 15%, median progression-free survival 24.6 vs. 23.9 months respectively, for FCR with and without lumiliximab). There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes. An interim analysis failed to show sufficient efficacy of the combination of lumiliximab with FCR. The study was therefore stopped early for lack of efficacy. Despite the eventual outcome, the LUCID trial is one of the largest studies that provides valuable insight into the efficacy and tolerability of FCR as a therapeutic option for patients with relapsed CLL.

Published
2014

32. Abstract CT085: Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL): CHRONOS-3 and CHRONOS-4

Author

Gerecitano, John F., primary, Zinzani, Pier L., additional, Zheng, HongXia, additional, Ito, Rodrigo, additional, Tanaka, Paula Y., additional, Mueller, Katharina, additional, Yuan, Jason, additional, and Childs, Barrett H., additional

Published
2016
Full Text
View/download PDF

33. Novel Therapies for Aggressive B-Cell Lymphoma

Author

Foon, Kenneth A., Takeshita, Kenichi, and Zinzani, Pier L.

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases
Abstract

Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.

Published
2012
Full Text
View/download PDF

34. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18- FDG PET/ CT quantitative parameters in the International Extranodal Lymphoma Study Group ( IELSG) 26 study.

Author

Ceriani, Luca, Martelli, Maurizio, Conconi, Annarita, Zinzani, Pier L., Ferreri, Andrés J. M., Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria G., Rigacci, Luigi, Giovanella, Luca, Zucca, Emanuele, and Johnson, Peter W. M.

Subjects
MEDIASTINAL tumors, B cells, POSITRON emission tomography, GLYCOLYSIS, PROGNOSIS
Abstract

The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography ( PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis ( TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score ( DS) showed a better positive predictive value. A model in which baseline TLG is combined with interim DS might identify patients with shorter progression-free survival. PET metrics combined with interim DS may allow early risk assessment and warrants further studies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia

Author

Tedeschi, Alessandra, primary, Benevolo, Giulia, additional, Varettoni, Marzia, additional, Battista, Marta L., additional, Zinzani, Pier L., additional, Visco, Carlo, additional, Meneghini, Vittorio, additional, Pioltelli, Pietro, additional, Sacchi, Stefano, additional, Ricci, Francesca, additional, Nichelatti, Michele, additional, Zaja, Francesco, additional, Lazzarino, Mario, additional, Vitolo, Umbero, additional, and Morra, Enrica, additional

Published
2011
Full Text
View/download PDF

36. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma

Author

Federico, Massimo, primary, Bellei, Monica, additional, Pesce, Emanuela, additional, Zucca, Emanuele, additional, Pileri, Stefano, additional, Montoto, Silvia, additional, Weisenburger, Dennis D, additional, Ruediger, Thomas, additional, Ko., Y. H., additional, Liang, Raymond, additional, Zinzani, Pier L., additional, Connors, Joseph M., additional, Foss, Francine M., additional, Horwitz, Steven M., additional, Polliack, Aaron, additional, and Vose, Julie M., additional

Published
2009
Full Text
View/download PDF

37. The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Author

Strauss, Sandra J., primary, Morschhauser, Franck, primary, Gramatzki, Martin, primary, Solal-Celigny, Philippe, primary, Zinzani, Pier L., primary, Engert, Andreas, primary, Coiffier, Bertrand, primary, Hoelzer, Dieter, primary, Teoh, Nick, primary, Wegener, William A., primary, Goldenberg, David M., primary, Horak, Ivan D., primary, and Lister, Thomas A., primary

Published
2005
Full Text
View/download PDF

39. Pathobiology of Primary Mediastinal B-Cell Lymphoma.

Author

Pilerp, Stefano A., Zinzani, Pier L., Gaidano, Gianluca, Falini, Brunangelo, Gaulard, Philippe, Zucca, Emanuele, Sabattini, Elena, Ascani, Stefano, Rossi, Maura, and Cavalli, Franco

Subjects
*PATHOLOGY, *LYMPHOMAS, *B cell lymphoma, *DRUG therapy, *RADIOTHERAPY, *HEMATOLOGY, *HISTOCOMPATIBILITY, *IMMUNOGLOBULINS
Abstract

Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgVH gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5' noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgVH gene mutations, and BCL- 6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgVH gene crippling mutations. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

40. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma (vol 378, pg 331, 2018)

Author

Connors, Joseph M., Jurczak, Wojciech, Straus, David J., Ansell, Stephen M., Kim, Won S., Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illes, Arpad, Picardi, Marco, Ewa Lech-Maranda, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L., Cunningham, David, Rosta, Andras, Josephson, Neil C., Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A., Huebner, Dirk, and Radford, John

41. (90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study

Author

Michele Cavo, Ginevra Lolli, Matteo Carella, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Pier Luigi Zinzani, Alice Morigi, Miriam Marangon, Laura Nanni, Lisa Argnani, Beatrice Casadei, Lolli, Ginevra, Argnani, Lisa, Broccoli, Alessandro, Marangon, Miriam, Pellegrini, Cinzia, Morigi, Alice, Casadei, Beatrice, Nanni, Laura, Stefoni, Vittorio, Carella, Matteo, Cavo, Michele, and Zinzani, Pier L

Subjects
business.industry, treatment-naïve, Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, MALT lymphoma, Hematology, medicine.disease, extra-nodal marginal zone B-cell lymphoma, Therapy naive, relapsed, Cancer research, medicine, 90Y ibritumomab tiuxetan, In patient, Extra nodal, Marginal zone B-cell lymphoma, business, Mucosa-associated lymphoid tissue, medicine.drug
Abstract

No abstract available.

Published
2020

42. Granulomatous tattoo reaction in a nivolumab-treated patient

Author

Pier Luigi Zinzani, Alessandro Pileri, Michela Starace, Alice Morigi, Claudio Agostinelli, Miriam Leuzzi, Annalisa Patrizi, Elena Sabattini, Pileri, Alessandro, Starace, Michela, Leuzzi, Miriam, Agostinelli, Claudio, Sabattini, Elena, Morigi, Alice, Zinzani, Pier L, and Patrizi, Annalisa

Subjects
Treated patient, medicine.medical_specialty, Text mining, Nivolumab, business.industry, medicine, MEDLINE, Dermatology, business
Abstract

N/A N/A

Published
2020

43. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma

Author

Mahsa Eskian, MirHojjat Khorasanizadeh, Pier Luigi Zinzani, Nima Rezaei, Eskian, Mahsa, Khorasanizadeh, MirHojjat, Zinzani, Pier L, and Rezaei, Nima

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, First line, Immunology, first line, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, rituximab, immune system diseases, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunology and Allergy, Survival rate, induction, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Antibodies, Monoclonal, Induction Chemotherapy, Immunotherapy, medicine.disease, Lymphoma, Consolidation Chemotherapy, Radiation therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Radioimmunotherapy, radioimmunotherapy, Rituximab, business, consolidation, 030215 immunology, medicine.drug
Abstract

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. The estimated deaths and new cases of NHL in the USA in 2018 have reached 19,910 and 74,680, respectively, with 5-year survival rate of 71%. Therapeutic interventions for NHL consist of chemotherapy, radiation therapy and immunotherapy. Radioimmunotherapy (RIT) is a potential alternative treatment for NHL that is currently used in different lines of treatment. Studies show that nuclear medicine physicians and radiation oncologists are not yet certain about the proper line for administration of RIT. Herein, we have reviewed the efficiency and toxicity of RIT as the first line of treatment, and discussed potential novel indications, and strategies such as modifying induction therapy and using rituximab maintenance to optimize the efficiency of RIT as the first line of treatment. Our review indicates that it is more logical to postpone conventional therapies to the second or third lines of treatment instead of RIT.

Published
2018

44. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

Author

Stefano Pileri, Pier Luigi Zinzani, Christine McIntosh, Luigi Scotto, Jennifer E Amengual, Enrica Marchi, Kelly Zullo, Matko Kalac, Fabio Fuligni, Pier Paolo Piccaluga, Laura K Fogli, Maura Rossi, Owen A. O'Connor, Danielle C Bongero, Marchi, Enrica, Zullo, Kelly M, Amengual, Jennifer E, Kalac, Matko, Bongero, Danielle, Mcintosh, Christine M, Fogli, Laura K, Rossi, Maura, Zinzani, Pier L, Pileri, Stefano A, Piccaluga, Pier P, Fuligni, Fabio, Scotto, Luigi, and O'Connor, Owen A

Subjects
hypomethylating agent, epigenetic therapy, DNA Methyltransferase Inhibitor, Hematology, Pharmacology, CHOP, Biology, preclinical models, Romidepsin, HDAC inhibitor, Hypomethylating agent, medicine, Doxorubicin, Epigenetics, Histone deacetylase, Epigenetic therapy, T-Cell Lymphoma, medicine.drug
Abstract

Summary T-cell lymphomas (TCL) are aggressive lymphomas usually treated with CHOP (cyclophsophamide, doxorubicin, vincristine, prednisolone)-like regimens upfront. Recent data suggest that TCL are driven by epigenetic defects, potentially rendering them sensitive to epigenetic therapies. We explored the therapeutic merits of a combined epigenetic platform using histone deacetylase inhibitors (HDACIs) and DNA methyltransferase inhibitors (DNMT) in in vitro and in vivo models of TCL. The 50% inhibitory concentration (IC50) values revealed romidepsin was the most potent HDACI, with an IC50 in the low nanomolar range. The combination with a hypomethylating agent produced synergy across all cell lines, which was confirmed in cytotoxicity and apoptosis assays. An in vivo xenograft study demonstrated inhibition of tumour growth in the combination cohort compared to the single agent. Gene expression array and global methylation profiling revealed differentially expressed genes and modulated pathways for each of the single treatment conditions and the combination. Most of the effects induced by the single agent treatment were maintained in the combination group. In total, 944 unique genes were modulated by the combination treatment, supporting the hypothesis of molecular synergism. These data suggest combinations of hypomethylating agents and HDACIs are synergistic in models of TCL, which is supported at the molecular level.

Published
2015

45. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

Author

Luigi Rigacci, Maurizio Martelli, Luca Ceriani, Manuel Gotti, Luca Giovanella, Caterina Stelitano, Pier Luigi Zinzani, Emanuele Zucca, Andrés J.M. Ferreri, Annarita Conconi, Barbara Botto, Maria Giuseppina Cabras, Peter Johnson, Ceriani, Luca, Martelli, Maurizio, Conconi, Annarita, Zinzani, Pier L, Ferreri, Andrés J M, Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria G, Rigacci, Luigi, Giovanella, Luca, Zucca, Emanuele, and Johnson, Peter W M

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Kaplan-Meier Estimate, Total lesion glycolysis, Prognostic factors, Mediastinal Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, B-cell lymphoma, prognostic factor, Primary mediastinal B-cell lymphoma, Prognostic models, Positron-emission tomography, Positron-emission tomography metrics, Hematology, medicine.diagnostic_test, business.industry, medicine.disease, Prognosis, Lymphoma, 030104 developmental biology, Positron emission tomography, positron-emission tomography metric, 030220 oncology & carcinogenesis, Extranodal lymphoma, Fdg pet ct, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, Radiopharmaceuticals, business, Glycolysis
Abstract

The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value. A model in which baseline TLG is combined with interim DS might identify patients with shorter progression-free survival. PET metrics combined with interim DS may allow early risk assessment and warrants further studies.

Published
2017

46. Pathobiology of primary mediastinal B-cell lymphoma.

Author

Pileri SA, Zinzani PL, Gaidano G, Falini B, Gaulard P, Zucca E, Sabattini E, Ascani S, Rossi M, and Cavalli F

Subjects
Diagnosis, Differential, Gene Rearrangement, Humans, Immunophenotyping, Lymphoma, B-Cell chemistry, Lymphoma, B-Cell genetics, Mediastinal Neoplasms chemistry, Mediastinal Neoplasms genetics, Neoplasm Proteins analysis, Neoplasm Proteins genetics, Proto-Oncogene Mas, Lymphoma, B-Cell pathology, Mediastinal Neoplasms pathology
Abstract

Controversy still exists over the response to therapy and prognosis of patients with primary mediastinal B-cell lymphoma (PMBL). Recent data from the International Extranodal Lymphoma Study Group (IELSG) suggest that a MACOP-B (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) chemotherapy regimen followed by radiotherapy may be a better induction strategy than other previously used treatments. Although the pathobiology of PMBL has been widely studied, its precise histology, phenotype, and molecular characteristics are still not clear. To date, phenotypic analysis has revealed the following phenotype: positivity for CD45 and CD20, but negativity for CD3, CD10, CD21, Class I/II major histocompatibility antigens, and a variety of other immunohistochemical markers. CD79a is generally detected, despite an absence of surface immunoglobulins (Igs). CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma. BCL-2 protein is usually expressed but there are few data describing the expression of MUM1/IRF4, PAX5/BSAP, BCL-6, or the B-cell transcription factors BOB.1, Oct-2, and PU.1. Cytogenetic studies reveal gains in segments of chromosome 9p, including amplification of the REL proto-oncogene and the tyrosine kinase gene JAK2. Other molecular findings include: C-myc mutations or rearrangements, p53 mutations, IgV(H), gene mutations, and bcl-2 and mal over-expression. bcl-6 mutations and bcl-2 gene rearrangements are generally absent, suggesting that PMBL is of pre-germinal center (GC) origin. However, two recent reports show isotype-switched Ig genes with a high frequency of somatic hypermutations as well as variants in the 5' noncoding region of the bcl-6 gene. The IELSG collected 137 PMBL cases for extensive pathologic review. Histologically, the lymphomatous growth was predominantly diffuse with sclerosis that induced compartmentalized cell aggregation. It consisted of large cells with varying degrees of nuclear polymorphism and clear to basophilic cytoplasm. Molecular analysis was performed on 40 cases and showed novel findings. More than half of the cases displayed bcl-6 gene mutations, which usually occurred together with functioning somatic IgV(H) gene mutations, and BCL-6 and/or MUM1/IRF4 expression. The present study supports the concept that PBML is derived from activated GC or post-germinal center cells. However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgV(H) gene crippling mutations.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results